Douglas M. Fambrough, III

2020

In 2020, Douglas M. Fambrough, III earned a total compensation of $6.6M as President and Chief Executive Officer at Dicerna Pharmaceuticals, a 31% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$345,000
Option Awards$3,880,000
Salary$575,000
Stock Awards$1,801,884
Other$19,468
Total$6,621,352

Fambrough received $3.9M in option awards, accounting for 59% of the total pay in 2020.

Fambrough also received $345K in non-equity incentive plan, $575K in salary, $1.8M in stock awards and $19.5K in other compensation.

Rankings

In 2020, Douglas M. Fambrough, III's compensation ranked 1,516th out of 13,090 executives tracked by ExecPay. In other words, Fambrough earned more than 88.4% of executives.

ClassificationRankingPercentile
All
1,516
out of 13,090
88th
Division
Manufacturing
567
out of 5,621
90th
Major group
Chemicals And Allied Products
205
out of 2,254
91st
Industry group
Drugs
171
out of 1,954
91st
Industry
Pharmaceutical Preparations
119
out of 1,459
92nd

Pay ratio

Douglas M. Fambrough, III's Pay$6,621,352
Median Employee's Pay$311,375
Pay Ratio

21

to 1

In 2020, the annual total compensation of Douglas M. Fambrough, III was $6,621,352.

The annual total compensation of the median employee at Dicerna Pharmaceuticals was $311,375.

The ratio of Douglas M. Fambrough, III's pay to the pay of median employee was therefore 21 to one.

Source: SEC filing on April 20, 2021.

Fambrough's colleagues

We found six more compensation records of executives who worked with Douglas M. Fambrough, III at Dicerna Pharmaceuticals in 2020.

2020

Ralf Rosskamp

Dicerna Pharmaceuticals

Chief Medical Officer

2020

John Green

Dicerna Pharmaceuticals

Chief Financial Officer

2020

Bob Brown

Dicerna Pharmaceuticals

Chief Scientific Officer

2020

James Weissman

Dicerna Pharmaceuticals

Chief Operating Officer

2020

Shreeram Aradhye

Dicerna Pharmaceuticals

Chief Medical Officer

2020

Douglas Pagán

Dicerna Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like